The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
27-May-25
$100 million
Target:
Emergency Care Partners
Advised Emergency Care Partners (“ECP”), a leading provider of emergency department management services and its majority owner Varsity Healthcare Partners (“VHP”) on a growth recapitalization transaction, inclusive of a $100 million preferred equity investment led by MidOcean Partners (“MidOcean”)
20-Feb-24
$1.9 billion
Target:
Audacy Inc.
Advising 1L Ad Hoc Group on the pre-packaged restructuring of Audacy, one of the largest multi-platform audio content and entertainment companies with 221 radio stations in 45 distinct markets
29-Jan-24
$4.8 billion
Target:
Digicel Group
Advised PGIM, Contrarian Capital Management, and GoldenTree Asset Management on the restructuring of Digicel Group, a communications and entertainment provider with operations in 25 Caribbean and Central American markets
04-Oct-23
$610 million
Target:
Lucky Bucks, LLC
Advised the Term Loan Ad Hoc Group to Lucky Bucks, one of the largest Class B coin operated amusement machine (“COAM”) route operators in Georgia, on Lucky Bucks’ financial restructuring and chapter 11 process
27-Sep-23
Undisclosed
Target:
Slayback Pharma LLC
Acquiror:
Azurity Pharmaceuticals
Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
19-Aug-22
$2.2 billion
Target:
GI Alliance
Acquiror:
Apollo Hybrid Value Fund
Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital
18-Jan-22
$321 million
Target:
Fusion Connect, Inc.
Acquiror:
N/A
Advised Fusion Connect, Inc., a leading service provider of cloud communications and secure network solutions with a focus on serving mid-market and enterprise businesses on its comprehensive balance sheet recapitalization
11-Mar-21
$725 million
Target:
Speedcast International Limited
Acquiror:
Centerbridge Partners L.P.
Advised the Ad Hoc Group of First Lien Lenders on the Chapter 11 restructuring of Speedcast International Limited (ASX:SDA)
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
09-Feb-21
Undisclosed
Target:
US Acute Care Solutions
Acquiror:
Apollo Hybrid Value Fund
Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson
24-Nov-20
$1.5 billion
Target:
Cirque du Soleil
Acquiror:
Ad Hoc Group of Lenders
Advised the Company on its CCAA and Ch.15 proceedings and $1.5bn sale through a Sale and Investment Solicitation Process (SISP)
19-Nov-20
$797 million
Target:
iQor Holdings Inc.
Acquiror:
N/A
Advised the ad-hoc Cross-Holder Group of lenders on the fully consensual Prepackaged Plan of Reorganization of iQor Holdings Inc., a business process outsourcing company
17-Nov-20
$497 million
Target:
Gannett Co., Inc.
Acquiror:
N/A
Advised Gannett Co., Inc., a news media and marketing solutions company, on the refinancing of ~$500mm of its term loan with convertible notes
01-Oct-20
$1.05 billion
Target:
Akorn, Inc.
Acquiror:
First Lien Term Loan Lenders
Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization
14-Jan-20
$760 million
Target:
Fusion Connect, Inc.
Acquiror:
N/A
Advised the Ad Hoc Group of 1L lenders with respect to Fusion's Chapter 11 proceeding
10-Jun-19
$NA
Target:
Book Publishing Business of F+W Media
Acquiror:
Penguin Random House
Advised F+W Media, a content and e-commerce company focused on a variety of special interest categories, on the sale of its book publishing business as part of its broader in-court restructuring
02-May-18
$3.7 billion
Target:
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
31-Oct-17
$2.0 billion
Target:
Hirslanden Private Hospital Group
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
06-Oct-17
$18.4 billion
Target:
Caesars Entertainment
Advised selected Second Lien Noteholders, including Canyon Capital Advisors, Mason Capital, Paulson & Co. and Soros Fund Management regarding Caesars Entertainment Operating Company’s Chapter 11 proceedings
25-May-17
$115 million
Target:
F+W Media
Advised F+W Media, a content and e-commerce company focused on a variety of special interest categories, on the out-of-court restructuring of its c.$100 million term loan and a $15 million new money investment from existing lenders
25-Jan-17
$325 million
Target:
Ad Hoc Group of Senior Secured Noteholders
Advised the Ad Hoc Group of Senior Secured Noteholders in connection with the restructuring of Goodman Networks.
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
19-Jan-16
$NA
Target:
Recepta Biopharma
Acquiror:
Inova Empresa Fundo de Investimento em Participações
Advised Recepta Biopharma on a capital raise
05-Aug-14
$NA
Target:
Gannett Co., Inc.
Advised Gannett Co., Inc. a media and marketing solutions company, on the spin-off of its Publishing business and the creation of two separate media companies: one focused on television broadcasting and digital marketing and one focused on newspapers.